SYLMAR, Calif.— Second Sight Medical Products, maker of the Argus II retinal prosthesis implant, announced Friday that it is planning for an initial public offering worth nearly $32 million.

In an SEC filing on Friday, the Sylmar, Calif.-based company said it plans to issue 3.5 million shares at $9 per share, which would trade on the NASDAQ exchange under the "EYES" symbol. The offering could commence as early as next week, pending SEC approval. Second Sight first filed for the IPO last August.

The Argus II is the first retinal prosthesis approved for sale by the FDA.Click here to see a presentation about Argus II that Second Sight made at the Argus II at Vision Monday’s 2012 Global Leadership Summit.